02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Eisai, Drugs for Neglected Diseases deal

DNDi and Eisai partnered to develop Eisai’s fosravuconazole to treat eumycetoma. DNDi will conduct a clinical trial next year in collaboration with the Mycetoma Research Center at the University of Khartoum (Khartoum, Sudan). Eisai will...
07:00 , Apr 17, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

AstraZeneca plc had a busy March, announcing five new public-private partnerships and the launch of its Open Innovation website to list additional partnership opportunities ( see "Selected public-private partnerships for March 2014"). One of the...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Japan BCG, Astellas, Dainippon Sumitomo, Eisai, Merck KGaA, Aeras, Drugs for Neglected Diseases initiative (DNDi), Liverpool School of Tropical Medicine (LSTM),

The Global Health Innovative Technology (GHIT) awarded $12.5 million as part of the second round of awards to four partnerships developing drugs and vaccines to treat schistosomiasis, Chagas disease, parasitic roundworms and tuberculosis. The awards...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Brain Factory, Eisai deal

Eisai granted Brain Factory exclusive rights to develop and commercialize E1224 in Japan to treat fungal infections, excluding Chagas disease. Brain Factory plans to start Phase I testing of the prodrug of ravuconazole to treat...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Eisai, Drugs for Neglected Diseases initiative deal

DNDi received a license to develop Eisai's E1224 to treat Chagas disease. The prodrug of the antifungal ravuconazole is in preclinical testing. Eisai will supply the compound and provide scientific expertise to DNDi, which will...